Search
for
Did you mean JAK2 inhibitor?
Sort by
Research 30 of 578
- Under Development JAK Inhibitors for Dermatologic Diseases
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Jak inhibitors in the treatment of alopecia areata - a literature review
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 MKG2D Lymphocytes of Alopecia Areata Patients
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- Janus Kinase inhibitors in dermatology: a review
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Pharmacological Treatment of Alopecia
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib